Le Lézard
Classified in: Health
Subject: MAT

Reliva CBD emerges as #1 best-selling US retail CBD company


NATICK, Mass., Jan. 9, 2020 /PRNewswire/ -- Natick, Massachusetts based company Reliva CBD ? a premium CBD company helmed by 24-year CPG veteran Miguel Martin? has quickly emerged as a leader in the burgeoning sphere of retail CBD product sales. Reliva is now the number one-selling retail CBD brand in the United States and has seen five products (among its wide selection of offerings) appear within the top 15 rankings in that field (IRI).

CBD Wellness Products

Nearly 7% of American adults report using CBD, and that number is rising quickly. CBD sales in 2018 are estimated to have been between $600 million and $2 billion. By 2025, CBD is conservatively projected to generate sales of $16 billion per year within the United States alone. Google trends show that searches for CBD are rising every year.

In an emerging, already congested (and often confusing) market, Reliva CBD has stepped forward as the foremost CBD retailer ?a brand synonymous with clarity, consistency, and compliance.  Approved by all national wholesalers, Reliva's products are currently sold in over 18,000 retail stores and enjoy exclusive distribution with many national retail chains.

Reliva consistently outsells the competition when it comes not only to its CBD gummies, but also in terms of its shots and tinctures, which sell more units per distribution point than the competition (IRI). Reliva's CBD cream and sticks outsell national non-CBD topical brands ? and Reliva CBD Wellness cream currently ranks #1 in overall sales (as well as $/ACV) while Reliva's CBD stick ranks #3 in overall sales and (#2 in $/ACV).

Reliva responsibly sources its CBD from licensed seed-to-flower hemp farms, and each batch of CBD extract that is utilized in Reliva products undergoes rigorous third-party testing, evidenced by a certificate of analysis (COA) for each and every batch. Products are only released to market upon successful completion of this testing, and each Reliva CBD Wellness product carries an item-specific batch code and expiration date? as well as a scannable QR code in order to direct consumers to the company's web site, which contains COAs for every batch of product produced.

It is not difficult to see why Reliva has achieved the following and consumer loyalty that it has. What makes this market leader stand apart in a crowded field of competitors is what the company calls the Reliva Difference.  From not making outlandish claims about its products (in fact, not making any claims at all, including not even allowing customers to make claims in their product reviews) to testing for pesticides, microbials, and other undesirable elements to age-restricting retail and online sales (e.g., website age gates and non-self-service retail displays), it is clear that Reliva has established the standard for responsible, compliant marketing.

For more information, please visit www.relivacbd.com

SOURCE Reliva CBD


These press releases may also interest you

at 08:10
FirstWave Bio, Inc., a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions, today announced plans to initiate a Phase 2a/2b study in patients with COVID-19,...

at 08:10
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. and that the global licensing collaboration agreement with Biogen for the development and commercialization...

at 08:05
Merck , known as MSD outside the United States and Canada, announced today a commitment to strengthen health systems affected by the COVID-19 pandemic. Through Merck for Mothers, the company's global initiative to help end preventable maternal...

at 08:05
A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills. Using ionic liquid technologies developed in the lab...

at 08:05
X4 Pharmaceuticals, Inc. , a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the...

at 08:05
i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund. Founded by...



News published on 9 january 2020 at 15:49 and distributed by: